Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.
Takeda
Masayuki
M
Department of Medical Oncology, Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan.
Okamoto
Isamu
I
Makimura
Chihiro
C
Fukuoka
Masahiro
M
Nakagawa
Kazuhiko
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D011799:Quinazolines / Q000008:administration & dosage; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib